Tak-475    (DrugBank: TAK-475)

1 disease
IDDisease name (Link within this page)Number of trials
79Homozygous familial hypercholesterolemia2

79. Homozygous familial hypercholesterolemia    [ 128 clinical trials,   105 drugs,   (DrugBank: 29 drugs),   8 drug target genes,   15 drug target pathways]
Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 128 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-003626-26-GB
(EUCTR)
14/06/200601/11/2005A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous familial hypercholesterolemiaA double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous familial hypercholesterolemia Treatment of primary dyslipidemia
MedDRA version: 8;Level: PT;Classification code 10058108
Product Name: TAK-475
Product Code: TAK-475
Takeda Europe R&D Centre LtdNULLNot RecruitingFemale: yes
Male: yes
40United Kingdom
2NCT00263081
(ClinicalTrials.gov)
November 20056/12/2005Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial HypercholesterolemiaA Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Co-administered With Current Lipid-lowering Therapy in Subjects With Homozygous Familial Hypercholesterolemia.HypercholesterolemiaDrug: Lapaquistat acetate and current lipid-lowering treatment;Drug: Current lipid-lowering treatmentTakedaNULLTerminated8 YearsN/ABoth44Phase 3United States;Canada;France;Israel;Poland;United Kingdom